SCHEMBL733362

SCHEMBL733362

O=c1c2c(F)cccc2nc(CNc2ncnc3[nH]cnc23)n1-c1ccccc1Cl

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 14/20 0.60
PIK3CD O00329 8/20 0.49
POLB P06746 1/20 0.44
RECQL P46063 1/20 0.44
PIK3CB P42338 6/20 0.43
PIK3CA P42336 4/20 0.43
PIK3R1 P27986 3/20 0.43
PIK3R2 O00459 1/20 0.43
ABCB11 O95342 1/20 0.43
HTR1A P08908 1/20 0.43
PTGS1 P23219 1/20 0.43
OPRM1 P35372 1/20 0.43
PRKDC P78527 1/20 0.43
SLC6A3 Q01959 1/20 0.43
PDE4D Q08499 1/20 0.43
PDE3A Q14432 1/20 0.43
PIK3C3 Q8NEB9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3203342 0.95 PIK3CG (0.57) PIK3CGPIK3CDPOLBRECQLPIK3CB
SCHEMBL3216891 0.93 PIK3CG (0.56) PIK3CGPIK3CDPOLBRECQLPIK3CB
SCHEMBL732684 0.90 PIK3CG (0.55) PIK3CGPIK3CDPOLBRECQLPIK3CB
SCHEMBL18391930 0.88 PIK3CD (0.57) PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1
SCHEMBL755175 0.88 PIK3CG (0.54) PIK3CGPIK3CDPOLBRECQLPIK3CB
SCHEMBL21755890 0.87 PIK3CG (0.49) PIK3CGPIK3CDPOLBRECQLPIK3CB
SCHEMBL3210287 0.87 PIK3CG (0.58) PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1
SCHEMBL27743809 0.87 PIK3CD (0.58) PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1
SCHEMBL735026 0.84 PIK3CG (0.77) PIK3CGPIK3CDPOLBRECQLPIK3CB
SCHEMBL735280 0.83 PIK3CD (0.55) PIK3CGPIK3CDPIK3CBPIK3CAPIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140154772-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2014-06-05 US claimed
US-8138195-B2 Inhibitors of human phosphatidylinositol 3-kinase delta ICOS CORPORATION (US) 2012-03-20 US claimed
EP-1278748-B1 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORP (US) 2011-03-23 EP claimed
EP-1885356-A2 PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION ICOS CORPORATION (US) 2008-02-13 EP claimed
EP-1755609-A1 METHODS FOR TREATING AND/OR PREVENTING ABERRANT PROLIFERATION OF HEMATOPOIETIC CELLS ICOS CORPORATION (US) 2007-02-28 EP claimed
EP-1750715-A1 METHODS FOR TREATING MAST CELL DISORDERS ICOS CORPORATION (US) 2007-02-14 EP claimed
EP-1750714-A1 PHOSPHOINOSITIDE 3-KINASE DELTA SELECTIVE INHIBITORS FOR INHIBITING ANGIOGENESIS VANDERBILT UNIVERSITY (US) 2007-02-14 EP claimed
WO-2006089106-A2 PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION ICOS CORPORATION (US) 2006-08-24 WO claimed
US-20060106038-A1 Methods for treating and/or preventing aberrant proliferation of hematopoietic cells ICOS CORPORATION (US) 2006-05-18 US claimed
US-20060079538-A1 Methods for inhibiting angiogenesis VANDERBILT UNIVERSITY 2006-04-13 US claimed
US-6949535-B2 for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one ICOS CORPORATION (US) 2005-09-27 US claimed
WO-2005067901-A2 METHODS FOR TREATING AND PREVENTING HYPERTENSION AND HYPERTENSION-RELATED DISORDERS MICHIGAN STATE UNIVERSITY (US) 2005-07-28 WO claimed
US-20050054614-A1 Methods of inhibiting leukocyte accumulation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-03-10 US claimed
US-20050043239-A1 Methods of inhibiting immune responses stimulated by an endogenous factor ICOS CORPORATION 2005-02-24 US claimed
WO-2005016348-A1 METHOD OF INHIBITING IMMUNE RESPONSES STIMULATED BY AN ENDOGENOUS FACTOR ICOS CORPORATION (US) 2005-02-24 WO claimed
WO-2005016349-A1 METHODS OF INHIBITING LEUKOCYTE ACCUMULATION ICOS CORPORATION (US) 2005-02-24 WO claimed
US-20040266780-A1 for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one ICOS CORPORATION 2004-12-30 US claimed
US-6800620-B2 CONTACTING LEUKOCYTES, OSTEOCLASTS WITH AN ENZYME INHIBITORS, A 9H-PURIN-3H-QUINAZOLIN-4-ONE DERIVATIVES, TREATING BONE-RESORPTION DISORDER, ANTIPROLIFERATIVE AGENTS TREATING LEUKEMIA CELLS ICOS 2004-10-05 US claimed
US-20030195211-A1 Inhibitors of human phosphatidylinositol 3-kinase delta ICOS CORPORATION 2003-10-16 US claimed
US-20020161014-A1 Purinyl substituted quinazoline-4-one derivatives ICOS CORPORATION, A DELAWARE CORPORATION 2002-10-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054614-A1 Methods of inhibiting leukocyte accumulation PI4KB, PIK3CD, PIK3CA PIK3CG 7/4885PIK3CD 2/4885POLB 561/4885
US-20140154772-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA PIK3CD, PIK3CA, PIK3CG PIK3CG 3/4885PIK3CD 1/4885POLB 760/4885
US-20020161014-A1 Purinyl substituted quinazoline-4-one derivatives PIK3CD, PIK3CA, PIK3CG PIK3CG 3/4885PIK3CD 1/4885POLB 1137/4885
US-20060079538-A1 Methods for inhibiting angiogenesis FLT4, KDR, PDGFRB PIK3CG 13/4885PIK3CD 6/4885POLB 1178/4885
US-20040266780-A1 for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one PIK3CD, PIK3CA, PIK3CG PIK3CG 3/4885PIK3CD 1/4885POLB 1633/4885
US-20050043239-A1 Methods of inhibiting immune responses stimulated by an endogenous factor PI4KB, PI4KA, PIK3CD PIK3CG 10/4885PIK3CD 3/4885POLB 2350/4885
US-20060106038-A1 Methods for treating and/or preventing aberrant proliferation of hematopoietic cells MCL1, NFATC1, MKI67 PIK3CG 57/4885PIK3CD 25/4885POLB 978/4885
US-20030195211-A1 Inhibitors of human phosphatidylinositol 3-kinase delta PIK3CD, PIK3CA, PIK3CG PIK3CG 3/4885PIK3CD 1/4885POLB 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.